Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2020 - 12 - 11 save search
Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
Published: 2020-12-11 (Crawled : 15:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.34%
H: 2.6%
C: 2.13%
breast cancer cancer positive treatment chmp her2+ her2- her2
Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Published: 2020-12-11 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.22%
H: 1.89%
C: 0.65%
positive chmp
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer
Published: 2020-12-11 (Crawled : 15:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.17%
H: 0.69%
C: 0.13%
cancer positive colorectal cancer chmp keytruda
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Published: 2020-12-11 (Crawled : 15:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.58%
H: 0.24%
C: -2.03%
positive treatment chmp urothelial carcinoma
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
Published: 2020-12-11 (Crawled : 14:01) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -24.63%
H: 8.19%
C: -37.11%
positive trial phase 2
Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
Published: 2020-12-11 (Crawled : 10:00) - biospace.com/
XERS | $1.73 -1.7% -1.73% 2M
|
Health Technology
|
| O: 6.36%
H: 8.74%
C: 5.06%
diabetes hypoglycaemia positive injection chmp children
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.